Currently, there are 90.08M common shares owned by the public and among those 87.36M shares have been available to trade.
The company’s stock has a 5-day price change of -3.67% and -30.00% over the past three months. IMUX shares are trading -30.00% year to date (YTD), with the 12-month market performance down to -27.08% lower. It has a 12-month low price of $0.97 and touched a high of $2.11 over the same period. IMUX has an average intraday trading volume of 886.21K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.33%, -14.34%, and -20.17% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Immunic Inc (NASDAQ: IMUX) shares accounts for 62.53% of the company’s 90.08M shares outstanding.
It has a market capitalization of $94.58M and a beta (3y monthly) value of 1.87. The earnings-per-share (ttm) stands at -$1.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.83% over the week and 7.43% over the month.
Earnings per share for the fiscal year are expected to increase by 54.30%, and 21.19% over the next financial year. EPS should shrink at an annualized rate of 15.50% over the next five years, compared to 31.12% over the past 5-year period.
Looking at the support for the IMUX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 25, 2024, with the firm’s price target at $10. Leerink Partners coverage for the Immunic Inc (IMUX) stock in a research note released on September 09, 2024 offered a Outperform rating with a price target of $5. B. Riley Securities was of a view on August 27, 2024 that the stock is Buy, while SVB Leerink gave the stock Mkt Perform rating on October 21, 2022, issuing a price target of $5. H.C. Wainwright on their part issued Buy rating on September 19, 2022.
